{"name":"Mythic Therapeutics","slug":"mythic-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPNmF0U1FzMC16Sk41OE56a0ZWUWJ6UTdkN0d5QXVIOG56a3dhZFQtVl8xZk9XenF5V19aamZ2andjWFZWbG9XdjVEMWZhdEwzTWdCTkJYWG96VWxvcGhmN0sySHM0NW9KQXBNazF2Z1Vnb0JYU2V4dUFkSzhSRzRibQ?oc=5","date":"2026-01-09","type":"pipeline","source":"BioSpace","summary":"Biopharmas Continued Staff Cuts in 2025 - BioSpace","headline":"Biopharmas Continued Staff Cuts in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPbzgyRWNoZm5KWGhLQ1RTQzhLdHI2LWVVMHhvX0ZiLXBiMGt6NlRoRWxMeGlUcFZrNHNERTJReF9lNkhzbE5MU0pGbVJNN1luOWhvWHRvdjdIS0puTHpNZ1Ata3gwZ1NlU0VJbzlRTWZLOE0yc1JUNUpJbThZYkpUc3M0QS1NclRVX01uVnZDN2xkXy1tSG5IWFpmMnZ0NTRjWGN2a05jYnR0YlJ4Z2pPUFl5Wk10QQ?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road - Fierce Biotech","headline":"Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9iVUFUYkF6aGt3akxZT0hGaW1LLTVITDlQdFFCYUZkc2IwaDJKSHZpQ1d2VmtPWldraV9yWm9idUZab0xqcWZzdXllQ1BIaF9WUGVxcFJMNWhPakFld2QzRVg2dElTbkZjVjdzcEY3QmtFRG96SzhTT25aMkY?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Biotech","summary":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter - Fierce Biotech","headline":"Fierce Biotech Layoff Tracker 2025: Voyager jettisons 30 staffers; Mythic and Areteia shutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNUE1LVVJmVmRvam16S0w0Z3NROHlqWG1mbkZjM0h5NzNNMmo4VmFjN3NwYzRzaktRRFBzaE1KR0E1UGFuRlZCVUhWOUFSWUlrdEt0UXg0d0xnWlB5N01uQXVlcEV1R3hUZUc5ZUw4dHdHY095VVU5R1Bnd1BPcms2OU1vYW1FaE5ZUGt3NQ?oc=5","date":"2025-09-23","type":"pipeline","source":"EyeWorld","summary":"Emerging cancer therapies and potential ocular impact - EyeWorld","headline":"Emerging cancer therapies and potential ocular impact","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-31","type":"trial","source":"Business Wire","summary":"Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Novel cMET- ADC, MYTX-011, in Non-Small Cell Lung Cancer at the American So","headline":"Mythic Therapeutics Presents Compelling Efficacy Data from its Phase 1 KisMET-01 Study Supporting Best-in-Class Potentia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQUlQweUtxZVFZOHZDdzhpRlNlSzJ6VmYtT0lxQy1aZ3pmVGtKMWVmYkRUTnFSZU9nVGRHOGhSendPVHREMDJRaTloVjQyd0tRVlpvbU9tY21DUlkySVpuanA0SFd3QWFWVGpNN191dkVueVh4UGVMdUJsWlFMSlVSbzBOd1J1ejUza283RUtvX1NrZWFUS3RjWQ?oc=5","date":"2025-05-25","type":"trial","source":"Endpoints News","summary":"The 20(+2) under 40: Your guide to the next generation of biotech leaders - Endpoints News","headline":"The 20(+2) under 40: Your guide to the next generation of biotech leaders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQWktlcTBFa0owTllOYUVUbGNKRG1vblZwUWZaNEtlZm1BWnlFRVJZU0tUbjF5WWlzZGpVWFlBZ1Y4dDhOMWlwMnlpVy1qMXNJUkhtSUtFUlJrRHJJVmFKZEpEZExnNHhjMVEtdVZLaXVxbEJOa0JmVGlGS0VKNnUzVGpycms4SERqODRTSW1IRlNPTENRaERYV3ZybEZNLW0xV0ptNXNBeExMZEh5YTJSbnotNTRhaUFLV0J4Nk9GQ05zZW1uWmtTWk9sOXZ2YXpaajBHeEtfcXJxbS1jQ2RwYmx1ZjZFR3RzQ1Jkbl9kYnU5anBvaE9GbEFLck5RNUtfN3VTd2ZiZFY5a2xZdFcxQm1wemJLczh2bkJtSUllTUgyTF93TmdwX0tvRjd5SXMwRVViVk80bExmMk80eXJUb01ra0M0Rm5TVlFUNDFpejZWWl9JdFN5NTY1a05uWUFS?oc=5","date":"2025-05-22","type":"trial","source":"Business Wire","summary":"Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential of Investigational cMET ADC, MYTX-011, in Non-Small Cell Lung Cancer - Business ","headline":"Mythic Therapeutics to Present Compelling Efficacy Data from Phase 1 KisMET-01 Study Supporting Best-in-Class Potential ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxOM21NWGJUU3VHRnF1NzFjNk1RelV4RGVxWXVYN19jNGhVNjZIekt5YktjYTRBejRQeGE2VWd6V0RESG92eldPZms4RDlFZ0kxWmdtb0Z2ODFtR1ZTQWJCM0Nha0p4YXhoazJrdV9rYzVUVDlxTnAyVXRMOTdkeTR1S3ZyMDJ3TW4xU3lQa0pNY1dzeGt1R0E4Xy14bFlISWJkck1WRUdDMTFzOW5YOWlHalB5ZmpZcWR2dGxNNTEzbGhyUklaZWtWMG9fTWU1NGtPRWRIS3AyanphRFhaYmQtTGRIX21YNkRKYS1aUDNRbFFjWnN3Ti1GX3JOc3Y?oc=5","date":"2024-10-17","type":"pipeline","source":"PR Newswire","summary":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight - PR Newswire","headline":"200+ Pharma Companies Vie for the Top Spot in the Expanding Antibody-Drug Conjugate Oncology Market | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxOSW9KV1VLUTgzbm9lajlSN2RXYkNkd2xydlM2RUNxTC1sY0lCcnhtbXVWc2ZWY3ZVaWo3YTNGRGdxWndqZU9RZ09KbHZWeXhWNzM0UTEyU2ZKMGVXRmFrNGFDMnRkNkhBLWxxLVQxSzNxdVEwWnBsN0hiand0MGR1VXhqa0FWN0tHdzFTZDBucw?oc=5","date":"2024-05-30","type":"pipeline","source":"Pharma Voice","summary":"Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges - Pharma Voice","headline":"Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPOVpSODBYLXFKc0VFUGVQVm1rNVdoUDFQRS01RnlUa1VtQ0hGaUFORlNqMGJ3NWlnaDB4TnNWNTFwdUIydExYUzExd1dzRk10amJSM0I2ZmM0T0pjYTZRLThsTmxsY2ljSzBDamZLNFFBeURHNnFPMDBqVTZIb0pmYjUyVlhhOGpnUmdCZUxHUGxnUTVEREVya2dB?oc=5","date":"2024-03-28","type":"pipeline","source":"citybiz","summary":"Mythic Therapeutics Appoints George Eliades, Ph.D., as CEO - citybiz","headline":"Mythic Therapeutics Appoints George Eliades, Ph.D., as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQb1ZoRHo5bXZkbkk1WWtDcHY4dkJRaHVBLUlnRkFqbXpxSF9qZHVpSmFFbURkYlNZM2dWVjJaandIYnpqMGpwdU1FSkxRX2xrZmtVTGVRMmtFcEZnQVR5eXlidTZIc1I0UGVSYkQwb0FMbXlpdEtiN01UUDdNWFVja0cxRUhFTlRjVWxXOFR5MEwwMW5qZUVsaEtHQzRvOUNSTmxEQ0VxWmhnMk9RSWY3clpITzE?oc=5","date":"2021-12-15","type":"pipeline","source":"MedCity News","summary":"Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs - MedCity News","headline":"Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbmtXV0w4ZXdPZU9kTVdjOXhxSVZEY0NjSmtiY3VhbUpRSmZoc2lOc1RTdS1DOUlKUkFhbmJTOU9IMWpzMEZsdVNOMnJKc3ZTRnpEYnl5NzNNMkxwOXJDekdIUjRjYzJSdGFWTFF1ZEFpRWdYbUVPV2JpeEUxWjlrMlhDQ2VmLVhaTEwzOUp2bElUdExlQkk1dmp2cDZhRXUydW81bURkQ3R5MTM1MlpJQWxYVnA5Q3My?oc=5","date":"2021-12-15","type":"pipeline","source":"BioSpace","summary":"Mythic Therapeutics Scores $103 Million to Make \"Safer and Smarter\" ADCs - BioSpace","headline":"Mythic Therapeutics Scores $103 Million to Make \"Safer and Smarter\" ADCs","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}